Education
About Us
Working with TipRanks
Follow Us
GoodRx Holdings (GDRX)
NASDAQ:GDRX
GDRX Stock Chart & Stats
$2.68
-$0.12(-2.72%)
At close: 4:00 PM EST
$2.68
-$0.12(-2.72%)
Day’s Range― - ―
52-Week Range$2.61 - $5.81
Previous CloseN/A
Volume261.88K
Average Volume (3M)1.94M
Market Cap
$909.68M
Enterprise Value$1.74B
Total Cash (Recent Filing)$273.53M
Total Debt (Recent Filing)$545.13M
Price to Earnings (P/E)31.2
Beta0.70
Next Earnings
Feb 26, 2026EPS Estimate
0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.08
Shares Outstanding105,468,834
10 Day Avg. Volume2,063,890
30 Day Avg. Volume1,942,391
Financial Highlights & Ratios
PEG Ratio-0.37
Price to Book (P/B)2.48
Price to Sales (P/S)2.26
P/FCF Ratio15.80
Enterprise Value/Market Cap1.92
Enterprise Value/Revenue2.18
Enterprise Value/Gross Profit2.39
Enterprise Value/Ebitda9.89
Forecast
1Y Price Target
$4.46Price Target Upside66.42% Upside
Rating ConsensusHold
Number of Analyst Covering10
EPS Forecast (FY)0.43
Revenue Forecast (FY)$816.09M
Bulls Say, Bears Say
Bulls Say
Pharma Manufacturer Solutions GrowthExpansion of the Pharma Manufacturer Solutions business with strong consumer-direct pricing momentum is providing a growing offset to the core revenue base and supporting margin recovery.
Subscription And Telehealth ExpansionLaunch of a telemedicine subscription for weight management and focus on subscription services leverages GoodRx’s large digital audience to build recurring revenue and cross-sell opportunities.
Weight-loss PartnershipPartnership with Novo Nordisk to offer lower-cost branded injectable weight-loss treatments through GoodRx’s platform creates a direct new revenue avenue and can attract high-value users to the service.
Bears Say
Competitive Pressure And Delayed MonetizationHeavy competition in direct-to-consumer health categories and expectations that new offerings will not meaningfully move the needle for several years limit near-term upside from the company’s diversification efforts.
Pharmacy Benefit Manager Contract ShiftsChanges in pharmacy benefit manager contracts toward net pricing increase uncertainty around reimbursement levels and could reduce the company’s win rate on prescription pricing services.
Retail Pharmacy Closures And MACs DeclineOngoing retail pharmacy closures are reducing monthly active consumers and prescription transaction volumes, creating a persistent headwind for traditional prescription discount revenue.
GoodRx Holdings News
GDRX FAQ
What was GoodRx Holdings’s price range in the past 12 months?
GoodRx Holdings lowest stock price was $2.61 and its highest was $5.81 in the past 12 months.
What is GoodRx Holdings’s market cap?
GoodRx Holdings’s market cap is $909.68M.
When is GoodRx Holdings’s upcoming earnings report date?
GoodRx Holdings’s upcoming earnings report date is Feb 26, 2026 which is in 36 days.
How were GoodRx Holdings’s earnings last quarter?
GoodRx Holdings released its earnings results on Nov 04, 2025. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.09 by -$0.01.
Is GoodRx Holdings overvalued?
According to Wall Street analysts GoodRx Holdings’s price is currently Undervalued.
Does GoodRx Holdings pay dividends?
GoodRx Holdings does not currently pay dividends.
What is GoodRx Holdings’s EPS estimate?
GoodRx Holdings’s EPS estimate is 0.09.
How many shares outstanding does GoodRx Holdings have?
GoodRx Holdings has 105,468,834 shares outstanding.
What happened to GoodRx Holdings’s price movement after its last earnings report?
GoodRx Holdings reported an EPS of $0.08 in its last earnings report, missing expectations of $0.09. Following the earnings report the stock price went up 2.147%.
Which hedge fund is a major shareholder of GoodRx Holdings?
Currently, no hedge funds are holding shares in GDRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
GoodRx Holdings Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$4.46 (66.42% Upside)
$4.46 (66.42% Upside)
Blogger Sentiment
Bullish
GDRX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 434.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.5%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-39.36%
12-Months-Change
Fundamentals
Return on Equity
4.90%
Trailing 12-Months
Asset Growth
-2.17%
Trailing 12-Months
Company Description
GoodRx Holdings
GoodRx Holdings, Inc., through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States. It also offers other healthcare products and services, including subscriptions, pharma manufacturer solutions, and telehealth services. It serves pharmacy benefit managers that manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was incorporated in 2015 and is headquartered in Santa Monica, California.
GDRX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflected a balanced view with significant growth in Manufacturer Solutions and brand partnerships, offset by declines in prescription transaction revenue due to external factors. The company is optimistic about future growth opportunities and strategic initiatives.View all GDRX earnings summariesGDRX Revenue Breakdown
73.41% Prescription transactions
12.58% Subscription
11.34% Pharma manufacturer solutions
2.67% Other
GDRX Stock 12 Month Forecast
Average Price Target
$4.46
▲(66.42% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---